1. Home
  2. AKAN vs INTS Comparison

AKAN vs INTS Comparison

Compare AKAN & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akanda Corp.

AKAN

Akanda Corp.

HOLD

Current Price

$13.76

Market Cap

12.8M

Sector

Health Care

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$3.71

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKAN
INTS
Founded
2021
2012
Country
Canada
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
12.4M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
AKAN
INTS
Price
$13.76
$3.71
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$38.00
AVG Volume (30 Days)
361.0K
24.4K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.19
52 Week High
$78.90
$8.06

Technical Indicators

Market Signals
Indicator
AKAN
INTS
Relative Strength Index (RSI) 42.01 15.91
Support Level $11.84 $0.31
Resistance Level $29.84 $8.06
Average True Range (ATR) 4.03 0.21
MACD -1.30 -0.06
Stochastic Oscillator 7.92 14.29

Price Performance

Historical Comparison
AKAN
INTS

About AKAN Akanda Corp.

Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: